The achievement of a fair market valuation is the goal of investor relations for any company. This principle applies to companies in any sector. However, biotech firms show an exception in this respect. The market valuation regarding biotech investor relations varies greatly and differs from the principles applied in the case of other companies. In each industry, the value of a company is based on expected profitability along with cash flows and other investments. However, biotech companies are expected to lose money in the short-term and medium-term. These firms are most likely to make money in the long run.

Biotech investor relations in a nutshell

Biotech companies are future-based. You can’t expect these firms to make money in the short run. Rather, you’ll see losses in the short as well as medium-term. As such, investor relations (IR) in biotech firms are distinct. Successfully playing the biotech IR game involves adherence to certain distinct guidelines. Let’s check the important parameters that measure IR in the case of biotech companies.


The principal asset of any biotech company is technology. However, technology is partially proven initially. It could be worth a fortune, but it all depends on its success. Many biotech firms get too enamored with the yet-unproven technology. If you’re the owner of a biotech firm, you should apply a pragmatic approach while substantiating your claims with respect to technology.

The good thing is biotech investors are a specialized force. Most of them have medical or scientific backgrounds. Despite this fact, your investment and technology stories ought to be concise, coherent, and compelling to convince investors.


Biotech stocks carry immense risks. Risk is considered the major parameter in biotech investor relations. Initially, biotech companies should overcome development risks, including the creation and development of a drug that will work and have a safety profile. Then there’s a regulatory risk.

Biotech firms are heavily regulated and need approval before offering their products for sale. These firms have to lay down an understandable and convincing roadmap through development and approval. Plus, they’ve to provide a watertight business plan for their final product.


Pharmaceutical is a big sector. Even small biotech companies with a successful product opportunity could become a sensation overnight. That means if you invest in a biotech company, you could reap huge returns on your initial investment. Biotech firms have to lay out a description of the opportunity for their potential products.

The value of the company is based on how successful the product will be and how long the development and approval process will last. Also, the average sales of the products should be accounted for. You should provide accurate estimates taking into account the various parameters, especially risks and opportunities.


Most biotech firms consume cash without delivering results. Many companies have to raise capital again and again for research and development purposes. Creating milestones is necessary for developing an event landscape favorable for sequential capital raises.

The sooner the company gets a breakthrough in the development of the drug, the better the results will be. Even minor success can translate to bigger returns and profitability. So, planning in view of the financial requirements and expected development of drugs is imperative for better biotech investor relations.

Looking for advice? Contact LifeSci Advisors!